Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. - Wikidata - wikimedia - TriplyDB

Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study.

Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study.

http://www.wikidata.org/entity/Q34022606

about

Membrane binding and bending in Ebola VP40 assembly and egress Animal models for Ebola and Marburg virus infections Assembly of Ebola virus matrix protein VP40 is regulated by latch-like properties of N and C terminal tails Viral hemorrhagic fevers: advancing the level of treatment Current ebola vaccines The 2014–2015 Ebola outbreak in West Africa: Hands On Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb Emerging targets and novel approaches to Ebola virus prophylaxis and treatment Transmission of Ebola virus from pigs to non-human primates Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques Ebola haemorrhagic fever Monitoring of Ebola Virus Makona Evolution through Establishment of Advanced Genomic Capability in Liberia Ebola virus disease and critical illness.Lipid nanoparticles for targeted siRNA delivery - going from bench to bedside Filoviruses: One of These Things is (not) Like the Other Addressing Therapeutic Options for Ebola Virus Infection in Current and Future Outbreaks Pre-symptomatic diagnosis and treatment of filovirus diseases Lipid nanoparticles as carriers for RNAi against viral infections: current status and future perspectives Standardization of the filovirus plaque assay for use in preclinical studies Mouse models for filovirus infections ZikaVR: An Integrated Zika Virus Resource for Genomics, Proteomics, Phylogenetic and Therapeutic Analysis Structure and function of the complete internal fusion loop from Ebolavirus glycoprotein 2.Development of RNA Aptamers Targeting Ebola Virus VP35 Knocking down disease: a progress report on siRNA therapeutics Current prospects for RNA interference-based therapies Progress toward in vivo use of siRNAs-II Rescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNA Preparing for Serious Communicable Diseases in the United States: What the Ebola Virus Epidemic Has Taught Us Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial Lipid-based vectors for siRNA delivery Ebola virus disease: What clinicians in the United States need to know.Updates in diagnosis and management of Ebola hemorrhagic fever.Monoclonal antibodies for the treatment of Ebola virus disease.Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials.Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead.A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity.Could the Ebola virus matrix protein VP40 be a drug target?CHO cell production and sequence improvement in the 13C6FR1 anti-Ebola antibody.Anti-HBV efficacy of combined siRNAs targeting viral gene and heat shock cognate 70.Possible leap ahead in filovirus therapeutics.

P2860

Q21131091-ABA1F379-8D93-4597-AE99-BC09547FFD52 Q21131118-7FA12C2C-69B3-4186-9A93-F1EE20ED165C Q21134356-D57DF884-7CCB-46BF-8528-BA4FF6E56E01 Q21245298-A6BCE8F1-8F35-4DA8-A377-933FED6A38BE Q21534720-5856176C-C1C0-4320-906C-5F7288239CE6 Q24049114-B201F999-5617-4173-836E-79EB9BB992BA Q24594601-CC896682-D1DE-421E-9BC4-51B522E61193 Q24597625-D70353D1-670D-4E7A-BD1B-C6E47FDC6CFF Q24612028-37777BC8-F0E1-4E4C-8563-7B60712AB3FE Q24612811-852CE49C-7E80-4462-84D6-EB09939CBFA1 Q24629338-E568EAEA-3F9C-4723-AEE3-00C0EA037792 Q24696012-07FBE52D-E786-455C-931B-0A821F8D2C63 Q26250274-B34DAD65-C640-45B0-BDA7-7F66A79F5715 Q26741449-A6E60199-F9E6-4FBC-8965-EECA47A71B56 Q26783063-9212684E-E1D1-46A3-85BA-00320C8501FE Q26801423-357FB066-3ED3-4C62-85AB-97EA23F4E2A1 Q26823831-13C5CFE6-2632-4D7C-BA1E-5E9196F0ED65 Q26859021-4A46CADC-49C3-40C8-A4D8-BAE9DCC3CF69 Q27000207-1AD7CBAB-1B00-406E-A395-2433204E6923 Q27011569-D809EE4B-166A-49CC-B3A2-04588BE85276 Q27468686-88F7F7A1-1B68-4949-9FCA-AA3F7D383373 Q27670489-F14E2FB3-0D8B-4C21-A13E-CEAD8940B8A2 Q27680060-C22635BD-C458-41E8-95B2-09D8833AA476 Q28082939-65662D46-60BC-4ED9-B819-4596188302F9 Q28235733-B7E86B78-9FBB-4A10-958F-BC0CD6297B77 Q28255877-A40C437C-6B48-4B3D-BEE1-45FCD86D92CA Q28396399-0590FE4E-AC14-4FAB-8B30-04446D9E5A07 Q28397866-8AC4394B-3CAD-4AA6-8927-25F9AE079E86 Q28551448-167EA50E-5CA4-41DD-AE56-D8101E795C20 Q28828356-60C2A27A-5D75-4C1A-A87B-B541CFD3E718 Q30203249-7D3ED546-0DF4-438B-BB7C-F0FBE4D91EF2 Q30238537-B4EFD26B-DF61-48C4-8607-A2AAF94A74E5 Q30245073-5D4F05A1-41F6-4ED3-9D85-7D2E61000734 Q30251949-428C3DEB-60F7-4633-8727-2301EB566E75 Q30252022-E2DD89A4-A321-4FD2-B947-58DB3B7284D4 Q30279239-2787B39C-1988-4127-A12C-07966DE1F43C Q30356113-E2EBC7E7-6CAB-4E19-96D8-D20C31D0F941 Q30383481-6EA1DC60-4112-43F2-B239-EC38969CAA7A Q30531035-91724740-25FF-49AE-A6DC-FC88EBCE4E42 Q33701830-C333E1D9-8F6E-4485-96BB-F0C47CB33ADE

P2860

Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study.

http://www.wikidata.org/entity/Q34022606

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Postexposure protection of non ...... nce: a proof-of-concept study.

@ast

Postexposure protection of non ...... nce: a proof-of-concept study.

@en

Postexposure protection of non ...... nce: a proof-of-concept study.

@nl

type

label

Postexposure protection of non ...... nce: a proof-of-concept study.

@ast

Postexposure protection of non ...... nce: a proof-of-concept study.

@en

Postexposure protection of non ...... nce: a proof-of-concept study.

@nl

prefLabel

Postexposure protection of non ...... nce: a proof-of-concept study.

@ast

Postexposure protection of non ...... nce: a proof-of-concept study.

@en

Postexposure protection of non ...... nce: a proof-of-concept study.

@nl

P1433

Q34022606-E9D440F8-453F-473C-BEDD-68D7BE25ACBD

P1476

Q34022606-9969D4F3-D307-4793-AC89-7A051A53EB97

P2093

Q34022606-48D576ED-3C1B-4DA0-85C7-AB85C23226B7

Q34022606-6AD538D3-E0AC-45EB-90D2-657579341238

Q34022606-735DDFFD-79DD-43CB-92BE-56F49FFFC35B

Q34022606-81EB67C7-941F-4987-A7AC-5134728EF5E2

Q34022606-9779924C-11A2-4740-AFDF-79D1FC6E9016

Q34022606-D49CC195-20DB-4A18-B76E-26AB37A7B148

Q34022606-F5D49A20-4A59-4E43-BE0B-E5110355ABC1

Q34022606-FC5CA910-A060-4A51-BD93-DAED76025872

P304

Q34022606-2B332DD1-EB48-4D73-901C-716DEB4B515E

P31

Q34022606-164DE8E9-4B5A-43C6-AE1E-19B289702651

P356

Q34022606-365182E2-C5C0-479F-A732-90096C8F2C6D

P407

Q34022606-B0416357-94D1-4D65-8E22-83F275C10354

P433

Q34022606-54AB7CA0-2040-4E4A-9906-5907A7DC4971

P478

Q34022606-B9F25B92-98D8-4D10-BAFE-677CC91B9530

P50

Q34022606-52B2EE36-3502-4482-8C9E-52D81AA8ABE8

Q34022606-81C3F3FB-D6EB-445C-A1AE-EFA9E3E00BD4

Q34022606-89EF6F7F-CC15-4C7A-A2DC-F9CBAA6726A7

Q34022606-BDBEFF01-C2DC-40F5-9778-52476AE3B978

P577

Q34022606-5416FC4A-FB81-4F32-9775-8DF9E7E99B01

P5875

Q34022606-4D1BFE81-BA29-4CA8-9AA6-12ADE0673542

P698

Q34022606-55EA171D-6ED5-4706-8E35-A923477DC16A

P921

Q34022606-7957A392-83F1-4C01-ABB9-24C01FD46799

P356

S0140-6736(10)60357-1

P1433

P1476

Postexposure protection of non ...... nce: a proof-of-concept study.

@en

P2093

Adam Judge

http://www.w3.org/2001/XMLSchema#string

Amy C H Lee

http://www.w3.org/2001/XMLSchema#string

Ian Maclachlan

http://www.w3.org/2001/XMLSchema#string

Iran Tavakoli

http://www.w3.org/2001/XMLSchema#string

Joan B Geisbert

http://www.w3.org/2001/XMLSchema#string

Marjorie Robbins

http://www.w3.org/2001/XMLSchema#string

Susan de Jong

http://www.w3.org/2001/XMLSchema#string

Vandana Sood

http://www.w3.org/2001/XMLSchema#string

P304

1896-1905

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0140-6736(10)60357-1

http://www.w3.org/2001/XMLSchema#string

P407

P433

9729

http://www.w3.org/2001/XMLSchema#string

P478

375

http://www.w3.org/2001/XMLSchema#string

P50

Joshua C Johnson

Thomas W Geisbert

P577

2010-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44638512

http://www.w3.org/2001/XMLSchema#string

P698

20511019

http://www.w3.org/2001/XMLSchema#string

P921